Table 3.
No. of Patients | 1‐Year Estimates (95% CI) | Log‐Rank P Value | |
---|---|---|---|
All | 456 | 0.26 (0.22–0.3) | |
ST elevation | |||
No | 386 | 0.26 (0.22–0.31) | |
Yes | 70 | 0.22 (0.13–0.33) | 0.28 |
Sex | |||
F | 161 | 0.26 (0.2–0.33) | |
M | 295 | 0.25 (0.2–0.3) | 0.77 |
Smoker | |||
No | 366 | 0.26 (0.22–0.31) | |
Yes | 80 | 0.24 (0.15–0.34) | 0.99 |
Cancer type | |||
All solid tumors | 279 | 0.29 (0.24–0.35) | |
Lymphoma/ leukemia | 150 | 0.20 (0.14–0.26) | |
Multiple cancer | 27 | 0.22 (0.09–0.39) | 0.07 |
Cancer status | |||
Advanced | 403 | 0.22 (0.18–0.26) | |
Limited | 53 | 0.53 (0.39–0.65) | <0.001 |
CAD | |||
No | 309 | 0.23 (0.18–0.28) | |
Yes | 145 | 0.31 (0.24–0.39) | 0.09 |
CVA | |||
No | 414 | 0.27 (0.23–0.31) | |
Yes | 33 | 0.14 (0.05–0.28) | 0.49 |
Hyperlipidemia | |||
No | 348 | 0.22 (0.18–0.27) | |
Yes | 92 | 0.40 (0.30–0.50) | 0.001 |
DM | |||
No | 342 | 0.26 (0.22–0.31) | |
Yes | 108 | 0.25 (0.17–0.33) | 0.50 |
HTN | |||
No | 227 | 0.22 (0.17–0.28) | |
Yes | 229 | 0.29 (0.24–0.35) | 0.13 |
Chest radiotherapy | |||
No | 367 | 0.28 (0.24–0.33) | |
Yes | 84 | 0.16 (0.09–0.24) | 0.0065 |
Chemotherapy | |||
No | 149 | 0.37 (0.29–0.44) | |
Yes | 291 | 0.20 (0.15–0.24) | <0.001 |
Aspirin | |||
No | 245 | 0.18 (0.14–0.24) | |
Yes | 211 | 0.34 (0.28–0.41) | <0.001 |
β‐Blocker | |||
No | 235 | 0.16 (0.12–0.21) | |
Yes | 221 | 0.36 (0.3–0.42) | <0.001 |
Statin | |||
No | 362 | 0.22 (0.18–0.27) | |
Yes | 94 | 0.39 (0.29–0.49) | <0.001 |
ACE inhibitor | |||
No | 409 | 0.25 (0.21–0.3) | |
Yes | 47 | 0.28 (0.16–0.41) | 0.28 |
Thrombolytic | |||
No | 449 | 0.26 (0.22–0.3) | |
Yes | 7 | 0.14 (0.01–0.46) | 0.73 |
Catheter‐based revascularization | |||
No | 441 | 0.24 (0.2–0.28) | |
Yes | 15 | 0.67 (0.38–0.85) | <0.001 |
Abbreviations: ACE, angiotensin‐converting enzyme; CAD, coronary artery disease; CI, confidence interval; CVA, cerebrovascular accident; DM, diabetes mellitus; F, female; HTN, hypertension; M, male.